Recently, the US FDA has approved newer antibody ‘Polatuzumab vedotin-piiq’ for the treatment of Diffuse Large B-cell Lymphoma. It can be effectively used in cases where multiple chemotherapies haven’t shown any results in treatment. Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. This type of cancer multiplies very quickly in lymph nodes and spreads to bone marrow, spleen, liver and other organs.
The symptoms of DLBCL include, Swollen lymph nodes Fever Recurring night sweats Weight loss Drug Information: Polatuzumab vedotin-piiq is a CD-79b antibody-drug conjugate. Dosage: It is administered as Intravenous infusion every 21 days for 6 cycle in combination with bendamustine and rituximab product. The recommended dose is 1.8mg/kg infusion for 90 minutes. Mechanism of Action: Polatuzumab Vedotin-piiq is an antibody- drug conjugate (ADC) which inhibits…
